关于参股公司部分股权转让完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 南京迈诺威医药科技有限公司（以下简称"迈诺威"）是合肥立方制药股份 有限公司（以下简称"公司"或"立方制药"）的参股公司，截至 2025 年 5 月 12 日，迈诺威注册资本为 525.6734 万元（人民币，下同），公司持有迈诺威 6.4984% 的股权。 公司于 2025 年 5 月 12 日召开第五届董事会第二十一次会议，审议通过了 《关于转让南京迈诺威医药科技有限公司部分股权的议案》，同意公司以 2,218.3748 万元的价格将持有的迈诺威 2.2184%的股权（对应注册资本 11.6614 万元）转让给成都元禾原点创业投资合伙企业（有限合伙）（以下简称"元禾创 投"）。同日，公司与元禾创投就本次股权转让事项签署了《股权转让协议》。 具体内容详见公司在《证券时报》和巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于转让参股公司部分股权的公告》（公告编号：2025-039）。 证券代码：003020 证券简称：立方制药 公告编号 ...

Core Viewpoint - The pharmaceutical sector, particularly innovative drug stocks, has gained significant attention in the capital market due to substantial transactions, policy benefits, and research outcomes, leading to a notable recovery in stock prices for many listed companies [1] Group 1: Market Performance - The Wind Innovative Drug Index (8841049) saw an increase of over 10% from May 15 to June 17, with total trading volume significantly rising during this period [1] - A total of 34 pharmaceutical companies announced share reduction plans, while 7 companies disclosed share buyback announcements during the same timeframe [2] Group 2: Share Reduction Plans - Key figures such as chairpersons and general managers from various companies, including Jiukang Biological and Kanglong Chemical, have announced plans to reduce their holdings, with reductions ranging from 0.93% to 4.8% of total shares [2] - The majority of these reductions are attributed to personal financial needs or debt repayment, with some aimed at optimizing shareholding structures [2] Group 3: Stock Price Movements - Certain companies, including Likang Pharmaceutical and Luoxin Pharmaceutical, experienced significant stock price increases of 28.71% to 30.28% during the same period, suggesting potential "high-level cashing out" scenarios [3] - Likang Pharmaceutical's stock surged following the approval of its product for ADHD treatment, indicating strong market interest due to limited competition [3] Group 4: Share Buyback and Increase Plans - Several companies, including Shanghai Laishi and Chengdu Xiandao, have announced share buyback or increase plans, reflecting confidence in their future value [6] - Shanghai Laishi's controlling shareholder plans to invest between 250 million to 500 million yuan in share purchases, emphasizing a commitment to stabilizing investor expectations [6][7] - Enhua Pharmaceutical's chairman also increased his holdings, demonstrating confidence in the company's growth prospects [8]

Group 1 - Aike Technology (688092.SH) shareholders plan to reduce their holdings by up to 826,906 shares, accounting for 1.00% of the total share capital within three months after 15 trading days from the announcement [1] - Aike Cyber (688719.SH) executives plan to reduce their holdings by up to 2.1927% of the total share capital, totaling 2,530,000 shares within three months after 15 trading days from the announcement [1] - Anpeilong (301413.SZ) shareholders plan to reduce their holdings by up to 2,952,058 shares, representing 3% of the total share capital [1] Group 2 - Chaohongji (002345.SZ) shareholders plan to reduce their holdings by up to 26,655,380 shares, accounting for 3% of the total share capital within three months after 15 trading days from the announcement [2] - Chunguang Technology (603657.SH) plans to reduce its holdings by up to 1,000,000 shares, representing 0.73% of the total share capital [2] - Dahongli (300865.SZ) controlling shareholder plans to reduce his holdings by 136,150 shares, accounting for 1.4230% of the total share capital [2] Group 3 - Electric Link Technology (300679.SZ) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 15,000 to 78,000 shares [2] - Guangge Technology (688450.SH) shareholders plan to reduce their holdings by a total of 990,000 shares, representing 1.50% of the total share capital [2] - Guorui Technology (300600.SZ) shareholders plan to reduce their holdings by 8,827,034 shares, accounting for 3% of the total share capital [3] Group 4 - Hailier (603639.SH) shareholders plan to reduce their holdings by up to 1,200,000 shares, representing 1% of the total share capital [3] - Haotong Technology (301026.SZ) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 20,965 to 47,250 shares [3] - Huamao Logistics (603128.SH) executives have reduced their holdings by 272,000 shares, while other executives did not reduce their holdings [3] Group 5 - Jiamei Packaging (002969.SZ) shareholders plan to reduce their holdings by a total of 9,483,239 shares, accounting for 1.00% of the total share capital [4] - Jiangsu Boyun (301003.SZ) shareholders plan to reduce their holdings by up to 971,333 shares through centralized bidding and 1,942,666 shares through block trading [4] - Jinchicken Co., Ltd. (300798.SZ) shareholders plan to reduce their holdings by 14,000,000 shares, representing 2.99% of the total share capital [4] Group 6 - Jingfang Technology (603005.SH) shareholders plan to reduce their holdings by up to 13,043,400 shares, accounting for 2% of the total share capital [5] - Jingjin Electric (688280.SH) shareholders plan to reduce their holdings through centralized bidding or block trading [5] - Kolon New Materials (920098) shareholders have not implemented reductions, while another shareholder reduced holdings by 651,667 shares, representing 0.8014% of the total share capital [5] Group 7 - Liangpinpuzi (603719.SH) shareholders plan to reduce their holdings by 4,010,000 shares, accounting for 1% of the total share capital [6] - Mike Audi (300341.SZ) executives plan to reduce their holdings by 546,350 shares, representing 0.11% of the total share capital [6] - Pinwa Food (300892.SZ) shareholders reduced their holdings by 711,300 shares, accounting for 0.72% of the total share capital [6] Group 8 - Qiu Le Seed Industry (831087.BJ) shareholders plan to reduce their holdings by up to 3,300,000 shares, representing no more than 1.9975% of the total share capital [6] - Qiu Tianwei (300939.SZ) shareholders reduced their holdings by 1,100,000 shares, accounting for 0.93% of the total share capital [6] - Rejing Bio (688068.SH) shareholders plan to reduce their holdings by 1,800,000 shares, representing 1.9416% of the total share capital [7] Group 9 - Saike Xide (688338.SH) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 250,000 to 235,000 shares [7] - Wancheng Group (300972.SZ) executives plan to reduce their holdings through centralized bidding [7] - Wentai Technology (600745.SH) shareholders plan to reduce their holdings by up to 24,891,577 shares through block trading and 12,445,788 shares through centralized bidding [7] Group 10 - Xiechuang Data (300857.SZ) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 10,500 to 18,900 shares [8] - Xinhongze (002836.SZ) controlling shareholder reduced holdings by 1,895,300 shares, decreasing ownership from 63.74% to 62.91% [8] - Panda Dairy (300898.SZ) shareholders reduced their holdings by 884,470 shares, accounting for 0.7133% of the total share capital [8] Group 11 - Oat Technology (688312.SH) controlling shareholder plans to reduce holdings by up to 2,912,000 shares, representing no more than 2% of the total share capital [9] - Youningwei (301166.SZ) shareholders plan to reduce their holdings by 1,208,500 shares, accounting for 1.41% of the total share capital [9] - Yuhua Tian (300815.SZ) shareholders plan to reduce their holdings by up to 23,915,520 shares, representing no more than 6.00% of the total share capital [9] Group 12 - Zhangzidao (002069.SZ) shareholders plan to reduce their holdings by up to 7,111,000 shares, accounting for no more than 1% of the total share capital [9] - Zhishang Technology (301486.SZ) shareholders reduced their holdings by 1,245,300 shares, accounting for 0.9677% of the total share capital [10] - Zhongjing Electronics (002579.SZ) shareholders plan to reduce their holdings by up to 6,000,000 shares through centralized bidding or block trading [10]

证券代码：003020 证券简称：立方制药 公告编号：2025-043 合肥立方制药股份有限公司 关于部分董事、监事、高级管理人员及股东减持股份的预披露 公告 公司董事王清女士、监事汪琴女士、高级管理人员戴天鹤先生和郑勇先生、 股东高美华女士保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 公司总股本比例 0.67%）的公司董事、副总经理王清女士计划减持公司股份合计 不超过 321,165 股（占公司总股本比例 0.17%）。 女士计划减持公司股份不超过 143,425 股（占公司总股本比例 0.07%）。 先生计划减持公司股份不超过 142,864 股（占公司总股本比例 0.07%）。 生计划减持公司股份不超过 104,130 股（占公司总股本比例 0.05%）。 交易日后的 3 个月内（即 2025 年 6 月 30 日至 2025 年 9 月 29 日）以集中竞价或 大宗交易方式进行。 士计划自本公告披露之日起 3 个交易日后的 3 个月内（即 2025 年 6 月 12 日至 股（占公司 ...

证券代码：003020 证券简称：立方制药 公告编号：2025-043 合肥立方制药股份有限公司 关于部分董事、监事、高级管理人员及股东减持股份的预披露 公告 公司董事王清女士、监事汪琴女士、高级管理人员戴天鹤先生和郑勇先生、 股东高美华女士保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 1、持有合肥立方制药股份有限公司（以下称"公司"）股份 1,284,660 股（占 公司总股本比例 0.67%）的公司董事、副总经理王清女士计划减持公司股份合计 不超过 321,165 股（占公司总股本比例 0.17%）。 2、持有公司股份 573,700 股（占公司总股本比例 0.30%）的监事会主席汪琴 女士计划减持公司股份不超过 143,425 股（占公司总股本比例 0.07%）。 3、持有公司股份 571,459 股（占公司总股本比例 0.30%）的副总经理戴天鹤 先生计划减持公司股份不超过 142,864 股（占公司总股本比例 0.07%）。 4、持有公司股份 416,520 股（占公司总股本比例 ...

Group 1 - The company, Lifan Pharmaceutical (stock code 003020), announced that several key personnel and shareholders plan to reduce their holdings in the company [1] - Board member Wang Qing intends to reduce his holdings by no more than 321,200 shares, accounting for 0.17% of the company's total share capital [1] - Supervisor Wang Qin plans to reduce his holdings by no more than 143,400 shares, representing 0.07% of the total share capital [1] - Senior management member Dai Tianhe aims to reduce his holdings by no more than 142,900 shares, also 0.07% of the total share capital [1] - Senior management member Zheng Yong plans to reduce his holdings by no more than 104,100 shares, which is 0.05% of the total share capital [1] - Shareholder Gao Meihua intends to reduce his holdings by no more than 300,000 shares, accounting for 0.16% of the total share capital [1] Group 2 - The reduction period for these shareholdings is set from June 30, 2025, to September 29, 2025, and from June 12, 2025, to September 11, 2025 [1] - The method of reduction will be through centralized bidding or block trading [1]

Investment Rating - The report upgrades the investment rating for the company to "Buy-B" [5][12]. Core Views - The company is expected to see a turnaround in performance due to the clearance of centralized procurement risks and the approval of the methylphenidate three-layer chip, which is anticipated to significantly boost revenue [6][12]. - The company reported a revenue of 1.518 billion yuan in 2024, a year-on-year decline of 20.11%, with a net profit of 161 million yuan, down 29.15% [6][12]. - In Q1 2025, the company achieved a revenue of 360 million yuan, a year-on-year increase of 7.98%, and a net profit of 38 million yuan, up 25.94% [6][12]. Financial Performance - The company’s gross margin improved to 69.16%, an increase of 17.68 percentage points year-on-year, while the net profit margin remained stable at 9.87% [6][12]. - The projected revenues for 2025, 2026, and 2027 are 1.919 billion yuan, 2.404 billion yuan, and 2.988 billion yuan, respectively, with corresponding net profits of 212 million yuan, 281 million yuan, and 370 million yuan [12][14]. - The earnings per share (EPS) are expected to be 1.11 yuan, 1.47 yuan, and 1.94 yuan for the years 2025, 2026, and 2027, respectively [12][14]. Market Dynamics - The company has seen significant growth in its industrial business, with an 18.92% increase in revenue, driven by the successful launch of several products [8][9]. - The approval of the methylphenidate three-layer chip is expected to open up a large market opportunity, with an estimated 23 million children and adolescents affected by ADHD in China [9][12]. - The company has established a strong position in the market with its proprietary controlled-release technology, which is a key competitive advantage [9][11].

Investment Rating - The report upgrades the investment rating of the company to "Buy-B" [4][9] Core Views - The company is expected to see a turnaround in performance due to the clearance of centralized procurement risks and the approval of the methylphenidate three-layer chip, which is anticipated to significantly boost revenue [4][9] - The company reported a revenue of 1.518 billion yuan in 2024, a year-on-year decline of 20.11%, but showed signs of recovery with a 7.98% year-on-year increase in Q1 2025 revenue [4][11] - The gross margin improved to 69.16%, up 17.68 percentage points year-on-year, indicating better cost management and product pricing strategies [4][11] Financial Performance Summary - In 2024, the company achieved a net profit of 161 million yuan, down 29.15% year-on-year, but Q1 2025 net profit increased by 25.94% year-on-year to 38 million yuan [4][11] - The projected revenues for 2025, 2026, and 2027 are 1.919 billion yuan, 2.404 billion yuan, and 2.988 billion yuan respectively, with corresponding net profits of 212 million yuan, 281 million yuan, and 370 million yuan [9][11] - The earnings per share (EPS) are expected to be 1.11 yuan, 1.47 yuan, and 1.94 yuan for the years 2025, 2026, and 2027 respectively, with price-to-earnings (P/E) ratios of 21.7, 16.4, and 12.4 [9][11] Market Position and Product Development - The company has successfully launched several products, including the methylphenidate sustained-release tablets, which are expected to capture a significant market share due to the high prevalence of ADHD among children and adolescents in China [7][8] - The company has established a strong position in the market for controlled-release formulations, leveraging its proprietary technology and a diverse product portfolio [7][8] - The marketing strategy has been optimized to ensure sustainable growth, focusing on enhancing terminal management and improving channel management [8]

近日，合肥立方制药股份有限公司（以下简称"公司"或"立方制药"）收到 国家药品监督管理局下发的多库酯钠《化学原料药上市申请批准通知书》。现将相 关情况公告如下： 一、《化学原料药上市申请批准通知书》主要内容 申请事项：境内生产化学原料药上市申请 化学原料药名称：多库酯钠 证券代码：003020 证券简称：立方制药 公告编号：2025-042 合肥立方制药股份有限公司 关于收到原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 二、多库酯钠的相关情况 多库酯钠是一种阴离子表面活性剂，通过物理性润滑肠道排便，其制剂多库酯 钠片用于慢性功能性便秘。截至本公告日，国家药品监督管理局药品审评中心原料 药登记数据显示，包括公司在内，仅有3家企业原料药登记状态为"A"（已批准在 上市制剂使用的原料），该品种进口原料药登记状态为"I"（尚未通过与制剂共同 审评审批的原料）。 三、对公司的影响及风险提示 多库酯钠原料药上市申请获得批准，将进一步丰富公司原料药产品管线，提升 公司市场竞争力。由于产品的生产和销售可能受到政策和市场等因素影响，仍具有 一定 ...

Core Viewpoint - The article discusses the rising trend of using "smart drugs" in high-pressure industries like finance and technology, highlighting both the demand for these drugs and the associated risks of misuse and legal issues [1][2][3]. Group 1: Market Demand and Supply - The first domestic "smart drug" was launched in April, leading to a surge in stock prices for the producing company, Lifan Pharmaceutical, which experienced five consecutive trading limit increases [1][14]. - The global ADHD drug market is projected to reach $14.71 billion by 2025, with a compound annual growth rate of 4.11%, indicating significant market potential for similar drugs [15]. - The only officially approved "smart drug" in China, "Zhuanzhu Da," has faced supply shortages due to high demand and limited production capacity, leading to difficulties for legitimate ADHD patients in obtaining the medication [10][12]. Group 2: Misuse and Legal Issues - Many individuals, particularly young professionals and students, are resorting to illegal means to obtain "smart drugs" like Adderall and Ritalin, often through online channels or underground networks [5][6][7]. - Reports indicate that a significant portion of users are motivated by academic pressures, with some even resorting to virtual currencies for cross-border purchases [6][7]. - The misuse of these drugs can lead to severe health risks, including addiction and various psychological and physical side effects, yet the allure of enhanced focus drives many to overlook these dangers [9][17]. Group 3: Industry Response and Future Outlook - Lifan Pharmaceutical's recent approval of a generic version of "smart drugs" is seen as a response to the supply-demand imbalance in the market, potentially alleviating some of the shortages faced by patients [16][17]. - The company plans to shift packaging operations to its domestic facility to increase supply efficiency, although challenges remain in meeting the high demand [13][17]. - The overall market for "smart drugs" is expected to grow, but the actual therapeutic benefits and risks associated with misuse continue to be a concern for healthcare professionals [17][18].